Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis.

Ann Med · 2026 · PMC12983810 · PMID 41820200

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Conversely, a trend toward a reduced risk of neutropenia was observed in the elotuzumab group (RR = 0.84, 95% CI: 0.69–1.03; p = 0.09; I 2 = 29%), although this did not reach statistical significance ( Figure 10B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.